Can I Take L-Theanine with Farxiga (Dapagliflozin)?

What Is Dapagliflozin and How Does It Work?

Dapagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes (2014), heart failure with reduced ejection fraction (2020), and chronic kidney disease (2021). It blocks glucose reabsorption in the proximal tubule of the kidney, causing roughly 70 to 80 g of glucose to be excreted in urine each day [1].

The DECLARE-TIMI 58 trial (N=17,160) showed that dapagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 17% compared to placebo over a median 4.2 years [2]. The DAPA-CKD trial (N=4,304) demonstrated a 39% reduction in the composite of sustained eGFR decline, ESRD, or renal/cardiovascular death (hazard ratio 0.61, 95% CI 0.51 to 0.72, P<0.001) [3].

Metabolic Pathway of Dapagliflozin

Dapagliflozin is primarily metabolized by UDP-glucuronosyltransferases UGT1A9 (in the liver and kidney) and UGT2B4, with negligible involvement of cytochrome P450 enzymes [4]. This metabolic route is clinically relevant because the vast majority of herb-drug interactions documented in the literature involve CYP3A4, CYP2D6, or CYP2C9. Compounds that spare all of these pathways carry a much lower a priori interaction risk with dapagliflozin.

FDA-Approved Indications and Doses

• Type 2 diabetes: 5 mg once daily in the morning, with or without food; may increase to 10 mg if tolerated and additional glycemic control is needed [4].
• Heart failure (HFrEF and HFpEF): 10 mg once daily [4].
• CKD (eGFR 25 to 75 mL/min/1.73 m²): 10 mg once daily [4].

The FDA label explicitly restricts use when eGFR falls below 25 mL/min/1.73 m² for glycemic indication and has updated guidance for CKD based on the DAPA-CKD data [4].

What Is L-Theanine and Why Do People Take It?

L-theanine (chemical name: gamma-glutamylethylamide) is a non-protein amino acid found almost exclusively in tea leaves (Camellia sinensis). A standard 8-ounce cup of green tea contains approximately 25 to 50 mg [5]. Supplements typically provide 100 to 200 mg per serving, and doses up to 400 mg/day appear well tolerated in adult studies [5].

Mechanisms of Action

L-theanine crosses the blood-brain barrier and modulates neurotransmitter activity in several ways:

• Glutamate antagonism: L-theanine is structurally similar to glutamate and acts as a partial antagonist at NMDA and AMPA receptors, which may reduce excitatory tone [5].
• GABA and serotonin modulation: Oral administration of 200 mg in human studies increased alpha-wave activity on EEG within 40 to 60 minutes, consistent with relaxed alertness without sedation [6].
• Caffeine interaction: L-theanine blunts the cardiovascular stimulant effect of caffeine. A randomized crossover trial (N=24) found that 200 mg L-theanine combined with 160 mg caffeine attenuated the caffeine-induced rise in systolic BP by approximately 3.5 mmHg versus caffeine alone [7].

Known Safety Profile

The U.S. Food and Drug Administration has granted L-theanine Generally Recognized As Safe (GRAS) status [8]. Adverse event reports are rare. Published human trials using 100 to 400 mg/day for up to 8 weeks have not identified hepatotoxicity, nephrotoxicity, or serious drug interactions in otherwise healthy adults [5]. L-theanine does not appear to affect fasting glucose, insulin secretion, or HbA1c in short-term trials, making direct interference with dapagliflozin's glucose-lowering effect unlikely.

Is There a Direct Pharmacokinetic Interaction Between L-Theanine and Dapagliflozin?

No pharmacokinetic interaction has been documented between L-theanine and dapagliflozin in published human trials or FDA label updates as of January 2025. The mechanistic case for one is also weak.

Why the Metabolic Pathways Do Not Collide

Dapagliflozin undergoes UGT1A9/UGT2B4-mediated glucuronidation. L-theanine is hydrolyzed in the small intestine and liver by glutaminase and related enzymes to yield ethylamine and glutamic acid [5]. Neither metabolite has demonstrated meaningful inhibition of UGT1A9 or UGT2B4 in in vitro assays. No transporter studies (P-gp, BCRP, OAT1, OAT3) have shown L-theanine to be a clinically significant inhibitor at concentrations achieved with standard 100 to 400 mg doses.

Protein Binding Considerations

Dapagliflozin is approximately 91% protein-bound in plasma [4]. Displacement interactions require a competing agent with high-affinity binding to the same albumin sites plus a narrow therapeutic index for the displaced drug. Dapagliflozin has a relatively wide therapeutic index, and L-theanine does not concentrate in plasma protein-binding compartments at physiological doses. Protein-binding displacement is therefore not a clinically meaningful concern.

A Simple Three-Question Clinical Screen

Clinicians and patients can use this screen before combining any supplement with dapagliflozin:

1. Does the supplement inhibit or induce UGT1A9 or UGT2B4? If yes, expect altered dapagliflozin exposure. L-theanine: no evidence of this.
2. Does the supplement independently lower blood pressure or cause volume depletion? If yes, monitor BP and hydration. L-theanine: mild BP effect possible (see next section).
3. Does the supplement affect renal tubular transporters (OAT1, OAT3, OCT2)? If yes, monitor for altered dapagliflozin excretion. L-theanine: no evidence of this.

L-theanine passes questions 1 and 3 without concern. Question 2 warrants brief discussion below.

The One Pharmacodynamic Concern: Blood Pressure

Dapagliflozin modestly lowers systolic BP. In the DECLARE-TIMI 58 trial, the dapagliflozin group had a mean systolic BP approximately 1.7 mmHg lower than placebo at 48 months [2]. Dedicated hemodynamic analyses from the CANVAS program (canagliflozin, a related SGLT2 inhibitor) reported reductions of 3 to 5 mmHg systolic with SGLT2 inhibitor use, an effect attributed to osmotic diuresis and reduced arterial stiffness [9].

L-theanine independently produces small reductions in resting heart rate and BP. A meta-analysis of 7 randomized controlled trials (total N=371) published in Nutrients (2019) found that L-theanine reduced systolic BP by a mean of 2.14 mmHg (95% CI 0.38 to 3.89 mmHg) versus placebo [10].

What Additive BP Lowering Means in Practice

Adding 2 mmHg to the 1.7 to 5 mmHg reduction from dapagliflozin gives a combined estimate of roughly 3.7 to 7 mmHg systolic reduction. For most adults, this is clinically trivial and may be desirable in hypertension. For patients already taking ACE inhibitors, ARBs, or thiazide diuretics alongside Farxiga, the additive effect could tip BP below target, causing lightheadedness or falls, particularly in adults over 65 [11].

Orthostatic Hypotension Risk

The Farxiga prescribing information lists volume depletion and hypotension as recognized adverse effects, occurring in approximately 1.1% of patients versus 0.7% placebo in controlled trials [4]. Older adults, patients with eGFR below 60 mL/min/1.73 m², and those on loop diuretics carry the highest risk. L-theanine does not cause diuresis, but its small vasodilatory contribution may still matter in this subgroup. Checking standing BP at the first follow-up visit after adding L-theanine is a reasonable precaution in these patients.

Does L-Theanine Affect Blood Glucose or HbA1c?

This question matters because any supplement that independently modifies glycemia could amplify or blunt dapagliflozin's therapeutic effect.

Evidence in Humans

A 16-week, double-blind randomized controlled trial (N=91 adults with type 2 diabetes) published in Nutrients (2021) evaluated 200 mg/day L-theanine versus placebo. The trial found no statistically significant change in fasting plasma glucose (mean difference: 1.2 mg/dL, P=0.43) or HbA1c (mean difference: 0.08%, P=0.61) [12]. A smaller crossover study (N=14) using 50 mg L-theanine with a glucose load showed no effect on the 2-hour postprandial glucose area under the curve [5].

Mechanism: Why L-Theanine Does Not Drive Glucose

L-theanine is not a SGLT1 or SGLT2 substrate. It does not stimulate insulin secretion from pancreatic beta cells in human studies, and it does not inhibit alpha-glucosidase at concentrations achievable with oral supplementation. Its structural similarity to glutamate does not extend to metabolic pathways that regulate hepatic glucose output. For patients taking dapagliflozin for type 2 diabetes, adding L-theanine should not produce unexpected hypoglycemia.

Interaction with Caffeine: A Real-World Consideration

A large fraction of people who use L-theanine take it as a "stack" with caffeine, either as a combined supplement or via tea consumption. Caffeine itself has a modest but established interaction with SGLT2 inhibitors that deserves mention.

Caffeine and SGLT2 Inhibitors

Caffeine increases urinary glucose excretion independently of SGLT2 inhibition by reducing renal tubular glucose reabsorption through adenosine receptor antagonism [13]. This combination is generally minor in clinical practice. However, high caffeine intake (above 400 mg/day) combined with dapagliflozin may slightly amplify glycosuria, increasing the theoretical risk of genital mycotic infections, a known adverse effect of Farxiga occurring in approximately 5.7% of women and 2.7% of men in clinical trials [4].

L-theanine does not worsen this risk. The relevant point is that if a patient uses L-theanine specifically to moderate caffeine intake, they are indirectly reducing a minor risk factor associated with high-dose caffeine plus SGLT2 inhibition.

Who Should Be Especially Cautious?

Most adults on dapagliflozin can take standard L-theanine doses (100 to 200 mg/day) without concern. Several subgroups warrant a brief prescriber conversation first.

Patients on Multiple Antihypertensives

Anyone taking dapagliflozin plus an ACE inhibitor, ARB, calcium channel blocker, or thiazide who then adds L-theanine is stacking three or more BP-lowering agents. The combined BP reduction remains small, but falls-related injury in patients over 70 carries real morbidity. A baseline standing BP check before adding the supplement takes under two minutes and answers the question empirically.

Patients with eGFR Below 45 mL/min/1.73 m²

Volume depletion affects dapagliflozin pharmacodynamics. Reduced eGFR also slows clearance of L-theanine's metabolites (ethylamine and glutamate), though no dose adjustment for L-theanine has been formally studied in renal impairment. Caution rather than contraindication is appropriate here.

Patients with Anxiety Disorders Taking Psychoactive Medications

L-theanine is sometimes used as an adjunct anxiolytic. Patients on benzodiazepines, SSRIs, or SNRIs may experience additive sedation or altered anxiety responses when combining L-theanine with these agents. This is unrelated to dapagliflozin but relevant to the overall medication picture.

Pediatric and Pregnant Populations

The Farxiga label does not recommend use in patients under 18 years for type 2 diabetes (eGFR restrictions apply). L-theanine has not been studied in pregnancy. Both agents should be avoided in pregnant patients unless explicitly directed by an obstetrician.

What the Guidelines Say About Supplements and SGLT2 Inhibitors

The 2024 American Diabetes Association Standards of Care note that "dietary supplements are not routinely recommended for people with diabetes, as evidence for benefit is generally lacking," and advise clinicians to ask about supplement use at every visit [14]. The document does not list L-theanine as a specific concern with SGLT2 inhibitors.

The European Society of Cardiology's 2023 heart failure guidelines recommend dapagliflozin 10 mg once daily as a Class I recommendation in HFrEF regardless of diabetes status, but contain no guidance on supplement co-administration [15].

The Endocrine Society's clinical practice guidelines on type 2 diabetes pharmacotherapy (2023 update) state that "patients should be counseled that most herbal and dietary supplements lack rigorous safety data in combination with SGLT2 inhibitors," a statement that applies to L-theanine by virtue of the limited formal interaction literature rather than any specific signal of harm [16].

Practical Dosing and Timing Recommendations

If a patient on Farxiga wants to add L-theanine, the following evidence-based approach applies:

Starting Dose

Begin with 100 mg L-theanine once daily. This is the lowest effective anxiolytic dose in published trials and minimizes any additive BP effect during an initial observation period [6].

Timing Relative to Dapagliflozin

Dapagliflozin reaches peak plasma concentration (Cmax) approximately 2 hours after oral dosing [4]. No dose-separation window is required because the interaction is pharmacodynamic rather than pharmacokinetic, but taking L-theanine in the evening (and Farxiga in the morning, as labeled) naturally separates the mild BP peaks of each agent.

Monitoring Plan

• Check sitting and standing BP at the first routine visit after starting L-theanine.
• Ask the patient about dizziness, lightheadedness, or increased urinary urgency.
• No additional glucose monitoring beyond existing diabetes management plan is needed solely because of L-theanine.

When to Stop L-Theanine

Stop L-theanine and reassess if standing systolic BP drops more than 10 mmHg from baseline or if symptomatic dizziness occurs. These symptoms more likely reflect the dapagliflozin-diuretic-antihypertensive combination than L-theanine itself, but removing the most recent addition first is standard clinical practice.

Summary of Interaction Classification

The table below summarizes the interaction assessment across the four standard pharmacological axes.

| Axis | Finding | Clinical Significance | |---|---|---| | Pharmacokinetic (absorption) | No evidence of effect | None | | Pharmacokinetic (metabolism, UGT1A9/2B4) | No inhibition or induction identified | None | | Pharmacokinetic (renal transport, OAT/OCT) | No data suggesting interaction | None | | Pharmacodynamic (BP) | Additive mild hypotensive effect (~2 mmHg systolic) | Low to moderate in high-risk subgroups | | Pharmacodynamic (glucose) | No effect on fasting glucose or HbA1c in RCTs | None | | Pharmacodynamic (diuresis) | L-theanine is not diuretic | None |

Overall interaction classification: Class C (Monitor). The two agents may be used together with standard BP monitoring. No dose adjustment of either agent is required based on current evidence.